DEXCOM INC

DEXCOM INC (ticker: DXCM) is an NASDAQ-listed surgical & medical instruments & apparatus company. Its most recent SEC filing was a 8-K dated 2026-05-15. DredgeCap's extraction of DXCM's SEC filings surfaces no active distress signals from the most recent annual filing. DXCM reported $1.19B in revenue and $199.50M for the period ending 2026-03-31, with operating cash flow of $525.60M. Cash and equivalents stood at $1.12B (up 23.6% year-over-year). Total assets of $6.63B exceed total liabilities of $3.68B. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.

← DXCM Overview

8-KMarch 2, 20263/2/26

DXCM — 8-K Filing

Track for Alerts

DXCM 8-K Summary

On March 2, 2026, DEXCOM INC filed an 8-K covering Departure / Election of Directors or Officers (Item 5.02) and Financial Statements and Exhibits (Item 9.01). Primary disclosure: DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.As previously reported on the Current Report on Form 8-K filed on July 30, 2025, Kevin R.

8-K Items Disclosed

Item 5.02 — Departure / Election of Directors or Officers

Officer or director change — appointment, resignation, retirement, or termination, plus compensation arrangements.

DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.As previously reported on the Current Report on Form 8-K filed on July 30, 2025, Kevin R. Sayer notified the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”) of his intent to retire from his role as Chief Executive Officer effective January 1, 2026. In connection with his retirement, on July 25, 2025, the Board appointed Mr.

Item 9.01 — Financial Statements and Exhibits

Press releases, exhibits, and supporting documents attached to this filing.

(d) Exhibits.NumberDescription10.1*Letter Agreement, dated February 27, 2026, between DexCom, Inc. and Kevin Sayer.104Cover Page Interactive Data File (formatted as Inline XBRL)*Represents a management contract or compensatory plan, contract or arrangement.SIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.DEXCOM, INC.By: /s/ JEREME M. SYLVAINJereme M. SylvainExecutive Vice President, Chief Financial OfficerDate:March 2, 2026

Structured financials are not available for this filing. View the original on SEC EDGAR for details.

Current DredgeCap Risk Profile

3.2/10

MODERATE RISK

Dilution Risk

LOW2.5/10

Liquidity Risk

LOW2.0/10

Debt Toxicity

MODERATE3.5/10

Profitability Risk

LOW2.8/10

Going Concern✓ Not flagged

The risk profile above reflects the latest cached DredgeCap analysis for DXCM. For the full filing-by-filing analyst report (red flags, primary risk driver, what moves the stock), open DXCM's company page.

What is a 8-K?

A current report disclosing a material event that occurred between regular reporting periods. Companies are required to file an 8-K within four business days of certain events including earnings releases, executive changes, acquisitions, debt obligations, restructurings, and material agreements. Each 8-K specifies one or more 'Items' identifying which event triggered the filing.

More on DXCM

Form-type explainers and 8-K item descriptions are derived from SEC documentation. Financial values are extracted from SEC-tagged XBRL — see the "Source filings" list above each table for direct EDGAR links to every cited filing. This page does not constitute investment advice. Always consult the original filing on SEC EDGAR for authoritative content, and consult a licensed financial advisor for investment decisions.